Bright Minds Biosciences (DRUG) Competitors $38.82 +4.02 (+11.55%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$39.35 +0.53 (+1.37%) As of 08/8/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. IMNM, ELVN, URGN, IOVA, MLYS, SANA, ZYME, ORIC, TRVI, and SNDXShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Immunome (IMNM), Enliven Therapeutics (ELVN), Urogen Pharma (URGN), Iovance Biotherapeutics (IOVA), Mineralys Therapeutics (MLYS), Sana Biotechnology (SANA), Zymeworks (ZYME), Oric Pharmaceuticals (ORIC), Trevi Therapeutics (TRVI), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Immunome Enliven Therapeutics Urogen Pharma Iovance Biotherapeutics Mineralys Therapeutics Sana Biotechnology Zymeworks Oric Pharmaceuticals Trevi Therapeutics Syndax Pharmaceuticals Immunome (NASDAQ:IMNM) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Which has higher earnings and valuation, IMNM or DRUG? Bright Minds Biosciences has lower revenue, but higher earnings than Immunome. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$9.04M93.30-$292.96M-$3.08-3.15Bright Minds BiosciencesN/AN/A-$2.06M-$0.36-107.83 Which has more volatility & risk, IMNM or DRUG? Immunome has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.07, meaning that its stock price is 707% less volatile than the S&P 500. Do analysts rate IMNM or DRUG? Immunome presently has a consensus target price of $23.14, suggesting a potential upside of 138.83%. Bright Minds Biosciences has a consensus target price of $83.25, suggesting a potential upside of 114.45%. Given Immunome's higher possible upside, equities analysts plainly believe Immunome is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is IMNM or DRUG more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Immunome's net margin of -1,687.08%. Bright Minds Biosciences' return on equity of -14.56% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-1,687.08% -78.93% -66.09% Bright Minds Biosciences N/A -14.56%-14.29% Do institutionals & insiders hold more shares of IMNM or DRUG? 44.6% of Immunome shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 8.6% of Immunome shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer IMNM or DRUG? In the previous week, Immunome had 11 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for Immunome and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.88 beat Immunome's score of 0.32 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Bright Minds Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBright Minds Biosciences beats Immunome on 9 of the 15 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.13M$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-107.8316.9029.7624.84Price / SalesN/A313.57449.1298.65Price / CashN/A41.8536.4258.36Price / Book42.207.318.185.64Net Income-$2.06M-$54.43M$3.26B$265.68M7 Day Performance15.43%0.00%6.79%4.90%1 Month Performance46.05%1.33%0.93%0.78%1 Year Performance3,381.61%8.64%28.83%22.16% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences2.228 of 5 stars$38.82+11.6%$83.25+114.5%+3,275.7%$245.13MN/A-107.83N/ANews CoverageUpcoming EarningsHigh Trading VolumeIMNMImmunome1.702 of 5 stars$10.95+3.4%$23.33+113.1%-25.1%$921.46M$9.04M-3.4440News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastELVNEnliven Therapeutics2.7073 of 5 stars$18.74+0.1%$41.20+119.9%-18.6%$919.07MN/A-9.7650Upcoming EarningsURGNUrogen Pharma4.604 of 5 stars$19.88+2.5%$32.86+65.3%+18.4%$896.31M$90.40M-6.25200Trending NewsEarnings ReportAnalyst ForecastGap UpIOVAIovance Biotherapeutics4.6624 of 5 stars$2.83+5.6%$12.22+331.9%-73.4%$894.94M$164.07M-2.28500Trending NewsEarnings ReportAnalyst ForecastGap DownMLYSMineralys Therapeutics2.1466 of 5 stars$13.03-4.6%$32.25+147.5%+16.4%$890.62MN/A-3.4928Upcoming EarningsSANASana Biotechnology3.2934 of 5 stars$4.23+8.2%$9.17+116.7%-35.6%$881.61MN/A-4.81380News CoverageUpcoming EarningsGap UpZYMEZymeworks3.2558 of 5 stars$12.60+0.2%$21.00+66.7%+17.8%$878.01M$93.38M-8.40460News CoverageEarnings ReportGap UpORICOric Pharmaceuticals4.1594 of 5 stars$9.74-3.8%$18.57+90.7%+4.6%$862.47MN/A-5.2180News CoveragePositive NewsUpcoming EarningsTRVITrevi Therapeutics3.1774 of 5 stars$7.49+2.2%$20.88+178.7%+165.0%$859.76MN/A-16.6420News CoverageEarnings ReportAnalyst ForecastSNDXSyndax Pharmaceuticals4.2154 of 5 stars$10.38+4.0%$34.10+228.5%-37.6%$858.75M$23.68M-2.69110Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Immunome Competitors Enliven Therapeutics Competitors Urogen Pharma Competitors Iovance Biotherapeutics Competitors Mineralys Therapeutics Competitors Sana Biotechnology Competitors Zymeworks Competitors Oric Pharmaceuticals Competitors Trevi Therapeutics Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts